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1. Introduction  
Despite advances in therapeutic approaches for patients with colorectal cancer (CRC), 
approximately 20-45% of those who undergo apparently curative surgery subsequently 
develop local or distant tumor recurrence (Harrison & Benziger, 2011). The liver constitutes 
the preferred metastatic site in approximately 30% of cases. According to the TNM staging 
system, a stage-specific 5-year survival rate of approximately 93% has to be expected for 
stage I, 72-84% for stage II, 44-83% for stage III and 8% for stage IV colon cancer (O’Connell 
et al., 2004). An early identification of patients at risk of developing metastatic disease after 
surgery would be of great importance for improving the clinical outcome. Currently, there 
are no reliable methods to identify patients who are at increased risk of relapse and in need 
of adjuvant chemotherapy. Aggressive postoperative treatment with cytotoxic drugs 
without certain indication leads to overtreatment of patients and severe side effects. 
Appropriate biomarkers for the identification of CRC patients at high risk for recurrence 
and/or poor prognosis are required to facilitate individually tailored therapy (Gangadhar et 
al., 2010). 
1.1 Biomarkers and CRC 
In general, an eligible biomarker in reference to chemotherapy is a characteristic that is 
objectively measured and evaluated as an indicator of response. A range of assays, 
including immunohistochemistry, gene analysis, gene and protein expression assessments 
and detection of single nucleotide polymorphisms (SNPs) have served to identify 
biomarkers in recent years (Saijo, 2011). Response rates to anticancer drugs applied in CRC 
may be as low as approximately 20% and, therefore, it is of great importance to identify 
patients most likely to benefit from a specific agent. For example, biomarkers such as 
expression of HER2 for breast cancer or EGFR mutation for lung cancer and KRAS mutation 
in CRC aid in selection of drug-sensitive patients. Personalized CRC care has improved 
patient outcome significantly over the last decades in both the adjuvant and metastatic 
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settings (Catenacci et al., 2011). Microarray-based gene expression profiling has been 
frequently used to formulate prognostic signatures and, to a lesser degree, predictive 
signatures in CRC; however, common problems associated with these markers are clinical 
study design, reproducibility and interpretation of the results (Van Schaeybroeck et al., 
2011).  
1.2 CRC and disseminated tumor cells (DTCs) 
Approximately 50% of CRC patients undergoing curative resection die from metastatic 
disease within 5 years and the relapse rate is 30% even in lymph node-negative patients 
(Iddings & Bilchik, 2007). Appearance of disseminated tumor cells (DTCs) in cancer patients 
may precede the occurrence of detectable metastases and, thus, may be used to adapt the 
aggressiveness of therapeutic regimens (Lugo et al., 2003; Pantel & Alix-Panabières, 2010). 
First evidence for such a role of bone marrow DTCs (BM-DTCs) or circulating tumor cells 
(CTCs), respectively, was obtained for breast cancer, where BM-positive patients had an 
approximately twofold increased risk of relapse within ten years (Braun et al., 2000). 
However, the situation is less clear for other solid tumors like CRC (Thorsteinsson & Jess, 
2011). Both solitary cells and micrometastases may remain in “dormancy” for years, being 
cell cycle arrested and not undergoing apoptosis (Luzzi et al., 1998). Cancer cells that left the 
primary tumor can seed metastases in distant organs, which is thought to be a unidirectional 
process. However, in a process that is called "tumor self-seeding" CTCs can also colonize 
their tumor of origin (Kim et al., 2009). 
As further discussed below, analysis of cytokeratins (CKs), either by RT-PCR, 
immunohistochemistry or quantification of soluble CK protein fragments released by tumor 
cells, is the mainstay of the detection of DTCs. Studies indicate that BM is a common 
homing organ and serves as reservoir for DTCs derived from various primary sites 
including tumors of the breast, prostate, lung and colon (Pantel & Alix-Panabières, 2010). 
However, peripheral blood analyses are obviously more convenient for patients than 
invasive BM sampling.  
1.3 CKs as marker of epithelial tumor cells 
Antibodies directed to CKs, that are members of the intermediate filament (IF) proteins, are 
useful tools particularly in the diagnostics of carcinomas (Barak et al., 2004; Karantza, 2011). 
These proteins protect epithelial cells from mechanical and non-mechanical stressors 
(Coulombe & Omary, 2002). At present, more than 20 different CKs have been identified, of 
which CKs 8, 18, and 19 are the most abundant in simple epithelial cells and carcinomas of 
the breast, prostate, lung, colon, ovary, among others (Moll et al., 1982; Bragulla & 
Homberger, 2009). Low molecular weight acidic type I CKs, such as CK18, are normally 
complexed with high molecular weight basic or neutral type II CKs, such as CK8. The bulk 
of cellular CKs are part of the IF system and mostly insoluble at physiological salt 
concentrations until they are cleaved to yield soluble fragments. CKs are in use for the 
detection of epithelial cancer cells in BM with the help of pan-CK antibodies directed to the 
CKs 8, 18, 19 and, furthermore, these proteins seem to be of functional importance for BM-
DTCs. Alix-Panabieres et al. demonstrated that full-length CK19 was shed by viable 
epithelial breast tumor cells and that such cells might constitute a biologically active subset 
of breast cancer cells with highly metastatic properties (Alix-Panabieres et al., 2009).  
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The production of soluble CK fragments may be triggered by hypoxia that has resulted in 
network disassembly and CK8/CK18 degradation (Na et al., 2010). Similarly, the keratin 
cytoskeleton in mammary epithelial cells disintegrates under metabolic stress of glucose and 
oxygen deprivation, which mimicks the tumor microenvironment (Nelson et al., 2004) 
Phosphorylation of CKs regulates their distribution into an insoluble filamentous cytoskeletal 
fraction and a soluble cytosolic hyperphosphorylated pool (Omary et al., 2006) and plays a 
role in CK ubiquitination and turnover by the proteasome (Ku & Omary, 2000; Jaitovich et al., 
2008) and, likely, by autophagy (Kongara et al., 2010). CKs released from proliferating or 
necrotic/apoptotic cells are useful markers for prediction of tumor progression/recurrence or 
response to therapy (Linder, 2007). The three most applied CK markers for the assessment of 
cell activity used in the clinic are tissue polypeptide antigen (TPA), tissue polypeptide-specific 
antigen (TPS) and CYFRA 21-1. The broad spectrum TPA test measures CKs 8, 18, and 19 
concentrations, while TPS and CYFRA 21-1 assays are more specific and determine CK18 and 
CK 19 levels, respectively (Linder, 2007). More recently, the ratio of caspase-cleaved (M30) to 
total CK18 (M65), which can be assessed in the serum or plasma using commercially available 
enzyme-linked immunosorbent assay (ELISA) kits, has been evaluated as a biomarker for 
monitoring therapy efficacy in carcinoma patients (Linder et al., 2010).  
2. Assessment of DTCs in CRC 
The prognosis of colon cancer patients is largely determined by the occurrence of systemic 
disease (Negin & Cohen, 2010). In patients with primary tumors relapse is mainly due to 
clinically occult micrometastasis that exists in secondary organs already at first presentation, 
but is not detectable with imaging procedures currently used (Riethdorf et al., 2008). 
Sensitive and specific immunocytochemical and molecular tests enable the assessment and 
characterization of DTCs at the single cell level in BM, which constitutes the common 
homing site of DTCs. Although many assays were developed to prove CTCs, two main 
approaches that are used involve either cytology based on immunocytochemical staining or 
polymerase chain reaction (PCR) analysis (Cristofanilli et al., 2007). Employing the US Food 
and Drug Administration (FDA)-approved Cellsearch® system, the value of CTCs as a 
predictive marker for survival was substantiated in metastatic breast cancer and CRC 
(Paterlini-Brechot et al., 2007). Still, there is an urgent need for standardized methods 
because of the high variability of results in the detection of DTCs and CTCs, respectively. 
2.1 Detection of DTCs by RT-PCR 
The detection of CTCs can be very difficult with as few as one CTC in 100 million leukocytes 
in peripheral blood and, thus, highly sensitive methods like PCR are employed to detect 
tumor-specific DNA or RNA. Since RNA is unstable and therefore disappears quickly from 
the blood after cell death, presence of RNA must be due to the occurence of viable tumor 
cells (Mostert et al., 2009). The RNA markers commonly used in CRC are carcinoembryonic 
antigen (CEA), CK19 and CK20 (Sergeant et al., 2008). The advantage of RT-PCR is a higher 
sensitivity compared to immunocytochemical techniques. Unfortunately, the specificity of 
RT-PCR is hampered by high numbers of false-positive results either due to contamination 
or target genes expressed in other nonmalignant cells. Novaes et al. demonstrated that 
mononuclear cells from peripheral blood of healthy donors express CK19 in RT-PCR assays 
(Novaes et al., 1997). Furthermore, both CEA and CK20 transcripts are elevated in patients 
www.intechopen.com
 
Cytokeratins – Tools in Oncology 
 
102 
with inflammatory diseases (Dandachi et al., 2005). Another important limitation of PCR-
based methods is that CTCs cannot be isolated for further analysis. Nevertheless, Allen-
Mersh et al. demonstrated that poor disease-free survival (DFS) was associated with the 
occurrence of CEA or CK20 24 hrs postoperatively using RT-PCR on blood samples from 
147 CRC patients with TNM-stage I-III tumors (Allen-Mersh et al., 2007). In another study, 
four RNA markers including human telomerase reverse transcriptase (hTERT), CK19, CK20 
and CEA mRNA were used to detect CTCs in stages II and III CRC patients who underwent 
curative resection to determine the significance of CTCs in prediction of early relapse (Lu et 
al., 2011). The presence of persistent postoperative CTCs was proved as independent 
predictor for early recurrence (hazard ratio: 11.04) and correlated with a poorer DFS and 
overall survival (OS). CK20 is a commonly used RT-PCR marker in analysis of BM from 
CRC patients; however, the number of investigated patients was larger than 100 with DTC 
detection rates of 11-35% only in 3 out of 10 studies. Two groups reported no association to 
survival in metastatic patients, whereas four groups found a correlation between the 
presence of CK20 transcripts and worse OS (Koch et al., 2006). 
Rahbari et al. also found postoperative tumor cell detection can predict poor recurrence-free 
survival in curatively resected CRC patients in a metaanalysis (Rahbari et al., 2010). The 
included studies reported postoperative detection rates of 22-57% DTCs in CRC with RT-
PCR. However, application of the RT-PCR approach is hampered by an absence of an 
international standard on choice of markers, enrichment procedures and laboratory 
techniques. Nevertheless, combining the TNM staging system and proof of CTCs could aid 
in decision-making as to which patients should be offered adjuvant chemotherapy.  
2.2 Detection of DTCs by immunohistochemical methods 
Immunohistochemistry utilizes labeled monoclonal antibodies directed against epithelial or 
tumor-associated antigens and automated digital microscopy or flow cytometry to isolate 
and count CTCs (Alix-Panabieres et al., 2008; Pantel et al., 2009; Allen & Keeney, 2010). This 
method allows identification of intact tumor cells occurring in the periphery for further 
characterization (Smirnov et al., 2005; Cohen et al., 2006). Most studies describing 
immunocytochemistry for the detection of DTCs in CRC patients either used the monoclonal 
antibody CK2 against CK18 or the pan-cytokeratin antibody A45-B/B3, while few studies 
employed a cocktail of several antibodies against different epithelial antigens including CKs. 
The DTC detection rate in studies with CK2 was 16-32%, whereas it was clearly higher in 
investigations using the A45-B/B3 antibody (24-55%). This difference might probably be 
due to a potential downregulation or loss of CK18 expression on DTCs (Pantel et al., 1994). 
Both antibodies rarely detect CK-positive cells in BM of noncancer control patients (0-5.5%). 
The largest study so far conducted by Flatmark et al. included 275 CRC patients and 206 
noncancer control patients (Flatmark et al., 2011). An immunomagnetic bead enrichment 
system capturing BM-DTCs by the antibody MOC31 directed against epithelial cell adhesion 
molecule (EpCAM) was applied and 17% of the patients showed presence of DTCs, whereas 
only 1.5% of control samples were positive. However, the BM status did not correlate 
significantly with disease stage or other clinical parameters, a finding we confirmed in a 
small series of patients (Buxhofer-Ausch et al., 2009). In conclusion, several studies were 
carried out to elucidate the clinical relevance of DTCs in CRC. These studies, however, 
present a very heterogeneous picture differing in patient groups, sample sizes, follow-up 
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times, staining methods and target antigens, all of which probably contributed to the 
observed variation in DTC detection rates and association to clinical parameters (Riethdorf 
et al., 2008).  
For the analysis of CTCs an automated microscopic system including an immunomagnetic 
tumor cell enrichment step was developed (Miller et al., 2010). This CellSearch System 
(Veridex LLC, Raritan, NJ) gained approval for metastatic breast cancer from the FDA in 
2004 and is now also accepted for metastatic prostate and colorectal cancer. In this detection 
method CTCs must feature: a round to oval shape by light scatter, an evident nucleus  
by DAPI staining, EpCAM positivity and CK8+, CK18+, CK19+ and CD45− by 
immunofluorescence (Allard et al., 2004). The sensitivity of approaches using EpCAM might 
be limited by the fact that EpCAM-negative CTCs would not be detected, which would lead 
to false-negative results. Rao et al. demonstrated that the expression of EpCAM on CTCs 
was approximately tenfold lower than on primary and metastatic tissues (Rao et al., 2005). 
The CellSearch CTC detection system was combined with a monoclonal antibody (M30) 
targeting a neoepitope disclosed by caspase cleavage at CK18 in early apoptosis (Rossi et al., 
2010). M30-positive CTC could be detected in >70% of CTC-positive carcinoma patients, 
which were free from both chemotherapy and radiologic treatments. The fraction of M30-
positive CTC varied from 50% to 80%, depending on the histotype.  
In a study by Sastre et al., CTCs were detected in 34 of 94 patients (Sastre et al., 2008). Only 
tumor stage correlated with positive CTCs (20.7% in stage II, 24.1% in stage III and 60.7% in 
stage IV). Cohen et al. demonstrated that the CTC level at baseline and follow-up is an 
independent prognostic factor in metastatic CRC. Patients were divided into unfavorable 
and favorable prognostic groups by their CTC levels of ≥3 or <3 CTCs/7.5 ml blood, 
respectively. PFS as well as OS was shorter for unfavorable compared with favorable 
baseline CTC patients (Cohen et al., 2009). Approximately one quarter of patients with 
metastatic disease thereby categorized in this poor prognosis group (Negin & Cohen, 2010). 
In a similar study by Tol et al. the CTC count before and during treatment with 
chemotherapy plus targeted agents independently predicted PFS and OS in advanced CRC 
patients (Tol et al., 2010). A metaanalysis of available studies to assess whether the detection 
of tumor cells in the blood and BM of patients diagnosed with primary CRC can be used as 
a prognostic factor included a total of 36 reports, comprising 3094 patients (Rahbari et al., 
2010). Pooled analyses that combined all sampling sites showed an association of the 
detection of tumor cells with poor DFS (hazard ration: 3.24) and OS (hazard ratio: 2.28). 
Now there is compelling evidence that CTCs predict clinical response in metastatic CRC 
(Allen & El-Deiry, 2010).  
Although the presence of CTCs can be a strong marker of poor prognosis in patients with 
metastatic disease, the prognostic role of CTCs in nonmetastatic CRC  (TNM stages I-III) is 
less clear (Thorsteinsson & Jess, 2011a). By using the CellSearch method to detect CTCs from 
blood samples taken 4-12 weeks after apparently curative surgery, Maestro et al. found >2 
CTCs/7.5 ml blood in 25 of 164 patients with localized CRC (Maestro et al., 2009). CTCs 
were detected with the CellSearch system preoperatively in one out of 20 patients with TNM 
stages I-III, and none of the four different postoperative blood samples had CTC levels 
above the cut-off value of ≥2 CTCs/7.5 ml blood (Thorsteinsson et al., 2011b). The presence 
of CTCs at least 24 hrs after CRC resection was suggested as independent prognostic marker 
of recurrence (Peach et al., 2010). It was concluded that the presence of CTCs in 
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nonmetastatic colon cancer is rare and barely detectable with the only commercially 
available assay for determination of CTCs, the CellSearch system. Further studies are 
needed to clarify the optimal time point for blood sampling and the benefit of chemotherapy 
in CTC-positive patients with stage II disease. The low incidence of CTCs in nonmetastatic 
CRC requires highly sensitive and specific detection methods. A gastrointestinal-specific 
anti-CK20 antibody was developed by Wong et al. and demonstrated to detect CTCs in 58 of 
101 patients with stage I-III CRC preoperatively and, furthermore, a decrease in CTCs in 51 
of these 58 patients after surgery  (Wong et al., 2009). Another study by this group found 
CK20 expression in lymph nodes and blood of CRC patients and a follow-up study reported 
that these cells predicted metastasis (Wong et al., 2009). 
Recently, it was observed that CTCs are often undetected in metastatic breast cancer patients 
treated with bevacizumab (Gazzaniga et al., 2011). Due to the frequent use of bevacizumab 
as first-line medication for metastatic CRC, the predictive value of the CTC count in patients 
treated with first-line chemotherapy plus bevacizumab compared with those treated with 
chemotherapy plus cetuximab was investigated. In the bevacizumab-treated patient group 
the median number of baseline CTCs was 2.7/7.5 ml blood and dropped to zero in most 
patients. However, half of the apparently CTC-negative patients proved to have progressive 
disease. Thus, bevacizumab-induced hypoxia in the primary tumor may generate a selected 
population of cells undergoing epithelial-mesenchymal transformation (EMT) with 
downregulation of epithelial markers such as EpCAM and CKs making these cells 
undetectable by the CellSearch system. Mego et al. for the first time used the term 
‘undetectable CTCs’ due to the obvious underestimation of CTCs that underwent EMT by 
the CellSearch system (Mego et al., 2011).  
2.3 Surgery and tumor cell dissemination 
Disturbing tumors mechanically, which may lead to shedding of cancer cells during 
surgery, constitutes a possible mechanism of tumor dissemination. The quantification of 
CTCs can be applied to assess the extent of this phenomenon. Lu et al. published a large-
scale study involving stage III and IV CRC patients who underwent curative resections. This 
study found that postoperative relapse was strongly correlated with laparotomy versus 
laparoscopic surgery, lymph node metastases, as well as CTC levels if elevated at both pre- 
and postoperative time points (Lu et al., 2011). In contrast, another study reported no 
statistically significant difference of the CD45-/CK+ tumor cell count in the blood at time of 
surgical incision, after tumor resection and at the end of operation (Tralhão et al., 2010). A 
similar result was published by Wind et al. for the respective type of operative procedures, 
revealing that the cumulative percentage of samples containing CTCs was significantly 
higher during open surgery as compared to the laparoscopic approach (Wind et al., 2009). 
However, dissemination of CK+ cells during surgery of hepatic metastases, a frequent event 
in colon cancer patients, did not predict extrahepatic recurrence (Schoppmeyer et al., 2006, 
Koch et al., 2007). In conclusion, CTCs seem to be generated during surgery; however, their 
significance for the occurrence of relapses is not clear. 
2.4 Epithelial-mesenchymal transition (EMT) and CKs 
EMT is considered an essential process in the metastatic cascade enabling the cells to aquire 
a mesenchymal cell phenotype characterized by increased motility and altered morphology 
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(Kalluri and Weinberg, 2009). The appearance of dot-like α-smooth muscle actin (α-SMA)-
staining in CK+ cells during tumor progression may indicate the initial phase of EMT in 
CRC (Valc et al., 2011). Increasing intraepithelial α-SMA concomitant with decreasing E-
cadherin expression points to a loss of epithelial cell contact in the beginning of EMT. 
However,  downregulation of epithelial markers like EpCAM and CKs in EMT-transformed 
tumor cells implicates the infeasibility to detect the most aggressive CTCs by methods 
relying on these markers (Mego et al., 2011). Epithelial cancer cells are likely to undergo 
EMT before they enter the peripheral circulation. Both EpCAM and CKs are downregulated 
as part of an oncogenic pathway promoting increased invasiveness and metastatic potential 
(Woelfle et al., 2004; Willipinski-Stapelfeldt et al., 2005). EpCAM is expressed in most but 
not all tumors and there is evidence for its modulation with cancer progression and 
metastasis (Mikolajczyk et al., 2011). Again, EpCAM expression may be suppressed to allow 
dissociation of epithelial cancer cells from the tumor and structural cytoplasmic CKs are 
downregulated to facilitate cell plasticity and migration. It is not always clear whether the 
loss of CKs is a result of independent oncogenic processes or whether it is always related to 
EMT. Aberrant occurrence of CKs in BM appears to be more common than in peripheral 
blood, and CK expression caused by inflammation can also contribute to false-positive 
observations (Dandachi et al., 2005). Although reduced expression of CK8 and CK20 is 
associated with EMT in CRC, which is generally indicative of higher tumor aggressiveness 
and decreased patient survival, several studies provided evidence supporting an active role 
of CKs in cancer cell invasion and metastasis (Knosel et al., 2006). Transfection of CK8 and 
CK18 into vimentin-positive mouse L fibroblasts resulted in higher migratory and invasive 
ability, indicating that CKs may influence cell shape and migration through interaction with 
the extracellular environment (Chu et al., 1993). Similarly, experimental coexpression of 
vimentin with CK8 and CK18 increases invasion and migration of human melanoma and 
breast cancer cells in vitro (Hendrix et al., 1997) 
EMT in breast tumor cells is characterized by upregulation of expression of vimentin, Twist, 
Snail, Slug and Sip1, among others (Kalluri and Weinberg, 2009). A recent study in early and 
metastatic breast cancer patients found that immunomagnetic separation of CTCs and triple-
immunofluorescence obtained with anti-CK/anti-Twist/anti-vimentin antibodies indicated 
that the mesenchymal marker could be coexpressed in the same CK+ cell, since 64% of the 
total identified CTCs were triple-stained (Kallergi et al., 2011). Among patients with early 
disease, approximately half of the CK+ CTCs were double-stained with anti-vimentin and 
anti-Twist antibodies, while the corresponding values for metastatic patients were 74% and 
97%, respectively. The median expression of CK+ vimentin+ and CK+ Twist+ cells per patient 
in metastatic patients was nearly 100% and in an adjuvant chemotherapy setting 
approximately 50%, respectively. The high incidence of  coexpressing cells in metastatic 
breast patients compared to early stage tumors point to a high metastatic potential of CTCs 
with EMT phenotype. Similar results were found for non-small cell lung cancer (NSCLC) 
and prostate tumor patients, where hybrid CTCs with an EMT phenotype coexpressing 
vimentin and CKs were detected (Lecharpentier et al., 2011; Armstrong et al., 2011). 
Furthermore, DTCs in BM may reverse EMT in a process termed mesenchymal-epithelial 
transition (MET) and regain an epithelial phenotype with loss of  mesenchymal migratory 
properties (van der Pluijm, 2011). Therefore, antibodies to CKs are still expected to help in 
the identification of tumor cells that underwent EMT, dependent on the respective 
histological origin. 
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2.5 CK-positive CTCs and cancer stem cells (CSCs) 
The CSC concept hypothesizes that tumors arise from a small population of stem cells, 
which may disseminate from the primary tumor to a stem cell niche until relapse. The 
relationship of cancer stem cells (CSCs) with CTCs is entirely unclear at this point. Thus, 
CTCs have additional intravasation and extravasation properties and, possibly, stem cell 
characteristics. CD133 (prominin) is one of the key markers of CSCs in CRC and CD133-
positive cells have high tumorigenic ability in nude mice (Smirnov et al., 2005). 
Furthermore, it was reported that CSCs are often characterized by downregulation of 
epithelial markers such EpCAM and CKs. Stem cell markers are frequently overexpressed in 
CTCs of patients with metastatic breast cancer. This stem cell-like subpopulation of CTCs is 
characterized by a nonproliferative and chemoresistant phenotype (Lianidou & Markou, 
2011). These facts would suggest that a new marker is necessary for the detection of CK-
downregulated, aggressive CTCs, which may comprise CSCs as well. The surface markers 
of colon CSCs, namely CD133, CD44, CD166, Musashi-1, CD29, CD24, leucine-rich repeat-
containing G-protein-coupled receptor 5 and aldehyde dehydrogenase 1 were reported 
(Dhawan et al., 2011). The clinical significance of CSC-like CTCs as a prognostic factor for 
OS and DFS in the peripheral blood of CRC patients was published (Iinuma, et al., 2011). 
CTCs of CRC patients who had undergone curative surgery expressed CEA, CK19, CK20 
and/or CD133 mRNA in peripheral blood. In particular, these CEA+/CK+/CD133+ CTCs 
demonstrated significant prognostic value in patients with Dukes' stage B and C cancer, but 
not Duke’s A. Again, this finding demonstrates that CTCs with CSC characteristics can still 
express CKs and may be detected with respective pan-CK antibodies. 
2.6 Soluble CK18 fragments as markers of residual tumor load  
There are several reports dealing with determinations of CK fragments in BM samples of 
cancer patients. An investigation using BM aspirates of breast cancer patients reported a 
positive relationship between the detection of micrometastic tumor cells in 
immunocytochemistry with the pan-CK antibody A45-B/B3 and measurements of CK 
fragment CYFRA 21-1 expression (Pierga et al., 2004). CYFRA 21-1 was significantly 
elevated in patients with disseminated tumors and both markers were associated with a 
poorer survival for patients with stage I to III breast cancer. The CK-positive cells in BM 
aspirates were reported to lack expression of urokinase plasminogen activator which  
is associated with metastasis (Werther et al., 2002). In order to avoid tedious 
immunohistochemical methods, a new enzyme immunoassay for detection of occult tumor 
cells in BM was developed that was designed to detect intracellular CK19 released from 
epithelial tumor cells after they had been lysed by freezing/thawing cycles (Riethmüller et 
al., 1997). Comparison of immunohistochemistry with this new assays revealed higher 
incidence of epithelial cells in advanced T-stage of CRC patients by the ELISA test. In 
comparison with controls, BM samples of cancer patients were found to have significantly 
elevated levels of CK19 and in the analysis of almost 400 BM aspirates of cancer patients, a 
significant correlation of ELISA and immunohistochemistry to detect CK+ cells was 
observed. However, most discordant samples were ELISA-positive and the CK status 
detected by this method did not correlate with the TNM stage and the histological grading. 
This immunoassay was reported to allow for sensitive and specific detection of DTCs in a 
faster, less laborious and more objective manner compared to immunohistochemistry.  
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Quantification of soluble CK fragments that are shed by epithelial tumor cells by newer 
methods may serve as an alternative way for detection of occult residual tumor load by DTC 
counting. In particular, CK18, an intracellular, mainly insoluble protein highly expressed by 
various types of epithelial cells, is released in form of a caspase-cleaved 30 kD (ccCK18) and 
a 65 kD fragment into the extracellular compartment during apoptosis and necrosis, 
respectively, though active export of intact CK19 has also been reported (Linder, 2011; Alix-
Panabieres et al, 2009). The 30 and 65 kD fragments can be quantified by the M30-
Apoptosense® ELISA and the M65® ELISA assay (Peviva, Bromma, Sweden), respectively. 
So far, a single study has been conducted in small cell lung cancer (SCLC) patients 
undergoing standard chemotherapy to evaluate cell death assays detecting CK18 fragments 
(ccCK18 and M65) and CTC profiles using the CellSearch system (Hou et al., 2009). In this 
study both ccCK18 and M65 correlated with known clinical and biochemical prognostic 
factors including tumor stage and expression of lactate dehydrogenase. The number of 
CTCs had prognostic significance and correlated with pretreatment M65 levels. The 
accordance between levels of the circulating apoptotic-specific protein ccCK18 and the 
proportion of morphologically apoptotic CTCs corroborate the role of ccCK18 to indicate 
tumor cell apoptosis. 
Although the levels of CKs in serum of cancer patients have been widely used for 
monitoring progression of tumor growth and effectiveness of treatment, the mechanisms 
of the release of CK fragments from cells is not clear (Linder et al., 2010). Studies in 
patients have shown that the release of CKs by tumors is a complex process, which seems 
to be not simply correlated to the number of proliferating cells or to the tumor mass but 
may also be dependent on the rate of cell damage (Oehr et al., 1997). During the 
development of CK18 as tumor marker the focus has switched from the perspective as 
proliferation marker to its significance as parameter of tumor cell death (Ausch et al., 
2010). The demonstration of elevated levels of both ccCK18 and M65 in venous blood 
from tumors of endometrial cancer patients proved that these proteins were derived from 
the malignant tissue (Kramer et al., 2004). Additionally, and in contrast to the assumption 
that CKs are only released in fragmented form by epithelial cells as a result of 
necrosis/apoptosis, evidence for the active release of full-length CK19 by viable epithelial 
tumor cells was published (Alix-Panabieres et al., 2009). According to this study CK19-
releasing cells were detected in BM of 44-70% of breast cancer patients and correlated to 
the presence of manifest metastases.  
2.6.1 Effect of radical tumor surgery on circulating CK18 fragments in CRC patients 
We quantified the CK18 fragments M65 and ccCK18 in serum samples of CRC patients pre- 
and postoperatively using ELISA assays and demonstrated higher levels of circulating M65 
and ccCK18 in patients with either low grade tumors or disseminated metastatic CRCs in 
comparison to nontumor control individuals. Due to tumor surgery approximately 60% of 
the CRC patients responded with a mean drop of soluble M65 blood levels of 30%, while the 
remaining 40% of patients showed a mean increase of 40%, respectively (Ausch et al., 
2009a). The group with increased postoperative levels of M65 was characterized by a higher 
incidence of BM-DTCs in comparison to patients with postoperatively normalizing M65.  In 
the case of circulating ccCK18 almost 80% of patients exhibited a significant decrease of 
approximately 75% in response to tumor removal; however, the remaining 20% revealed a 
www.intechopen.com
 
Cytokeratins – Tools in Oncology 
 
108 
mean increase of 40% of these CK fragment levels postoperatively (Ausch, et al., 2009b). The 
frequency of BM-DTCs, as detected before surgery with help of the pan-CK antibody A45-
B/B3, was not significantly different for these two groups of patients with normalizing and 
increased ccCK18 levels. However, the course of ccCK18 correlated well with an increased 
number of recurrences in the group with persisting serum fragment levels within a follow-up 
of three years (hazard ratio: 8.3). In conclusion, radical removal of the tumor, which is 
supposed to be the main source of the circulating CK18 fragments, failed to result in a decline 
of M65 levels to normal values in this subgroup of patients characterized by occurrence of BM-
DTCs and increased risk of early relapses. In the same group of CRC patients the overall rate 
of BM-DTCs detected was 23% independent of the respective tumor stage. No difference was 
found in relapse and OS between patients with or without BM-DTCs preoperatively after a 
median follow-up of 35.4 months (Buxhofer-Ausch et al., 2009). The BM-DTC status was found 
to be changed for a second BM aspiration after twelve months in a quarter of the patients. 
Thus, failure to yield postoperative reduction of circulating CK18 fragments in individual CRC 
patients seems to be indicative of remaining tumor tissue. 
CTCs released during surgery may undergo apoptotic cell death due to a failure of homing 
of the majority of cells to a suitable environment, while a minor fraction eventually manages 
to settle at distant sites and causes tumor recurrence (Rossi et al., 2010). Retsky et al. 
suggested that surgery to remove the primary tumor often terminates the dormancy DTCs 
resulting in accelerated relapses, as demonstrated in over half of the metastatic cases (Retsky 
et al., 2008). Another explanation for the CK release may be intracellular degradation of 
CK18 by caspases and shedding into the circulation as part of EMT without cell death or, 
alternatively, secretion of CK18 in intact form, as exemplified for CK19, followed by 
cleavage by caspases in the BM or serum (Alix-Panabieres et al, 2009). 
2.6.2 Course of M65 concentrations in BM aspirates of CRC patients 
In the present study we extended the measurement of M65 to BM aspirates of CRC patients 
obtained preoperatively and one year after surgery using the methods described by Ausch 
et al. (Ausch et al., 2009a).  
2.6.2.1 Patients and methods 
A total of 56 patients with colorectal cancer who were treated between January 2002 and 
December 2004 at the Donauspital, Vienna and had a follow-up period of more than 3 years. 
30 patients underwent surgery for primary colorectal carcinoma and none of the patients 
had received chemotherapy and/or radiotherapy prior to surgery. All patients were 
checked for infections by viral tests, blood count and chemistry, including determination of 
C-reactive protein. Twenty-three nontumor patients admitted to the outpatient department 
for minor complaints served as controls. Collected blood was centrifuged 2000 rpm for 10 
minutes and stored at -20 °C. Written informed consent was obtained from all patients. The 
study was approved by the local ethics committee and the institutional review board. BM 
aspirates were obtained from both upper iliac crests (5ml each) by needle aspiration 
immediately prior to the operation under general anesthesia. Mononuclear cells of bone 
marrow aspirates were separated by Ficoll-Hypaque density gradient centrifugation (GE 
Healthcare, Little Chalfont, UK). Cytospins containing 1x106 cells/slide were fixed in 
acetone and stained using pancytokeratin pan-CK antibody A45-B/B3 (Micromet, Munich, 
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Germany; final concentration 5 μg/ml; 20 min). All staining steps, including blocking and 
washes, were performed using the Idetect-Super- Stain-(alkaline phosphatase)-Fast-Red kit 
according to the manufacturer’s instruction (ID Labs, London, ON, Canada) and mouse 
monoclonal isotype controls were included. For assessment of BM-DTCs at least 2x106 cells 
per specimen were screened blinded by two pathologists and a minimum of one tumor cell 
per 2x106 mononuclear cells was regarded as a positive result for A45-B/B3. From all BM 
aspirates the concentrations of ccCK18 and and total CK18 (M65) were determined using the 
M30-Apoptosense® and the M65-ELISA assay® according to the manufacturer’s instruction 
(Peviva, Bromma, Sweden), respectively. The coefficient of variance for the duplicate 
measurements of M30/M65 was < 7.5%.  
2.6.2.2 Result of determinations of M65 in BM aspirates of CRC patients 
The comparison of M65 concentrations determined from 30 CRC patients is shown in Figure 
1. In the group of 16 patients with significant reduction (>10 %) of BM M65 levels, four cases 
of local relapses (Pat. # 2, 14, 52 and 68) were observed, whereas all four systemic relapses 
(Pat. # 3, 11, 43 and 45) occured in the second group who exhibited increasing M65 levels or 
minor reduction of  <10%. Thus, the difference in respect to systemic relapses was highly 
significant (0/16 versus 4/14; 0 versus 28.6%; p <0.001; Fisher’s exact test). Mean differences 
of M65 for the two groups and the two time points were -42.5 ± 17.2% and +12.3 ± 19.2%, 
respectively. Obviously, the determination of BM M65 levels is not adequate to predict local 
relapses in CRC patients, but systemic relapses in this small group of CRC patients 
correlated with perioperative changes in this CK fragment. The course of BM M65 levels 
during the first postoperative year was studied for the BM DTC-positive and -negative 
groups. Assessment of the BM for pan-CK-positive tumor cells by inspection of two million 
mononuclear cells showed no correlation with the course of M65 for the first year after 
surgery: M65 decreased by -24.0 ± 36.8% for the BM-DTC-positive (n = 15) and by -9.8 ± 
28.0% for the BM-DTC-negative patient group (n = 15), respectively. The former group 
comprised two systemic relapses while the latter exhibited two systemic and one local 
relapses (difference not significant). Although BM-DTCs were detected in 50% of these CRC 
patients, the status of BM did not correlate with the frequency of relapses during the follow-
up of five years. However, analysis of BM-DTCs was performed without any enrichment of 
tumor cells and the analysis of CTCs actually seems to be more suitable to obtain prognostic 
results (Allen & El-Deiry, 2010). In most cases, concentrations of M65 in BM and peripheral 
blood showed good correlation (Olszewski-Hamilton et al., 2011). In conclusion, a reduction 
of BM M65 concentrations during the first postoperative year points to PFS in respect to 
systemic disease, whereas an increase or a minor reduction seems to be associated with 
residual tumor load and systemic recurrence. Increased preoperative or pretreatment blood 
concentration of M65 was described as independent prognostic parameter, possible 
reflecting tumor burden of the individual patients. However, the individual time courses of 
CK fragments may more accurate mirror the effects of tumor treatment. Although 
determination of the individual differences in circulating CK18 levels before and after tumor 
surgery is prone to interference by inflammation and benign disease, it represents a cost-
effective alternative to the expensive automated counting of CTCs in nonmetastatic CRC. 
However, these results were obtained in a small group of CRC patients and need to be 
confirmed in a larger study. 
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Fig. 1. Comparison of the differences of BM M65 concentrations in two CRC patient groups 
between preoperative and follow-up samples taken one year later. 30 patients were 
classified into a group of 16 showing significant reduction (>10%) of the BM M65 
concentrations during the first year after surgery (A) and a group of 14 patients exhibiting 
<10% reduction of M65 (B). Data are shown as mean values (SD <10%).  
3. Conclusions 
Dissemination of tumor cells from primary tumors in the circulation seems to be an early 
event in tumor development for specific histological types. The presence of these DTCs in 
peripheral blood, bone marrow and distant organs is tested for providing the rationale for 
adjuvant systemic treatment (Bidard et al., 2011; Lin et al., 2011). Detection of DTC in bone 
marrow aspirates from breast cancer patients and other solid tumors at the primary 
diagnosis impacts the prognosis of disease. Technological advances in immunological and 
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quantitative real-time PCR-based analysis allow for detection, enumeration and 
characterization of disseminated tumor cells in cancer patients. Proof of the expression of 
CKs by use of antibodies is the mainstay of most methods to detect DTCs and gain 
prognostic data of patients with carcinomas. Despite assumed downregulation of epithelial 
markers like CKs, during EMT they are still expressed in vimentin-positive hybrid CTCs 
and allow for the assessment of tumor dissemination. Determinations of individual courses 
of the levels of circulating CK fragments before and after tumor surgery in blood or BM of 
CRC patients seem to constitute a valuable technique to prove residual tumor load, 
provided that these CK fragments are not released due to nontumor causes. The advantage 
of measuring CK fragments in the circulation or BM aspirates may be the sensitive detection 
of DTCs independent of their localization. For reliable results in regard to systemic relapses 
careful monitoring of individual time courses of the levels of the CK fragments in tumor 
patients seem to be necessary.  
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